Skip to main content

Table 1 Health care resource use hATTR amyloidosis best supportive care by NT proBNPa status

From: Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis

Best Supportive Care (BSC)

HCRU PNb (1-year cost)

HCRU CMc (1-year cost)

NT proBNP< 3000 pg/mL

221

18,375

4077

18,375

6295

18,375

11,455

18,375

16,397

18,375

167,247

18,375

NT proBNP≥3000 pg/mL

221

25,982

4077

25,982

6295

25,982

11,455

25,982

16,397

25,982

167,247

25,982

  1. aN-terminal pro b-type natriuretic peptide; b: Healthcare resource use, polyneuropathy; c: Healthcare resource use, severe cardiomyopathy